Prostate Cancer

Apalutimide Combo Significantly Improves Survival Outcomes in nmCRPC

May 30, 2020

Apalutimide in combination with androgen deprivation therapy led to a significant improvement in overall survival in patients with nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN clinical trial.

PSMA-Targeted PET Tracer Outperforms Standard Diagnostic Modalities in Relapsed Prostate Cancer

May 30, 2020

“The CONDOR study met its primary endpoint. Indeed, it well exceeded it. And it demonstrated excellent diagnostic performance of PyL PET in men with biochemically relapsed prostate cancer, even at very low PSA values."

PyL PET Tracer May Be Superior to Standard Imaging for Prostate Cancer

May 30, 2020

"The CONDOR study met its primary endpoint. Indeed, it well exceeded it. And it demonstrated excellent diagnostic performance of PyL PET in men with biochemically relapsed prostate cancer, even at very low PSA values."

Relugolix May Replace Current Standard of Care for T-Suppression in Advanced Prostate Cancer

May 30, 2020

"Relugolix is a novel, oral GnRH antagonist that has the potential to become a new standard for ADT in advanced prostate cancer."

Novel LuPSMA Appears More Active in Metastatic Castration-Resistant Prostate Cancer

May 29, 2020

“Lu-PSMA is a novel class of therapy with high activity and relatively low toxicity, consistent with the results of prior single-center studies in phase II data. Lu-PSMA appears to represent a favorable treatment option compared to cabazitaxel in a selected population with high PSMA-expression.”

Assay Shows Value for Patients With Low-Risk Prostate Cancer

May 25, 2020

Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.

Tweet Chat Recap: Sequencing Strategies for a Post-Docetaxel Patient with Metastatic Castration-Resistant Prostate Cancer

May 21, 2020

In an interview with Targeted Oncology, following a tweet chat on prostate cancer, Tian Zhang, MD, discussed the key takeaways from the tweet chat discussion and highlighted both the role of molecular testing and the impact of the recent FDA approvals in prostate cancer.

FDA Approves CDx Tests for Olaparib in HRR-Mutant mCRPC

May 20, 2020

Two companion diagnostic assays were granted FDA approval to identify male patients with metastatic castration-resistant prostate cancer who are eligible for treatment with olaparib.

FDA Approves Olaparib for HRR-Mutant mCRPC

May 19, 2020

The FDA has approved olaparib for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious germline or somatic HRR gene mutations and have progressed following prior treatment with a new hormonal agent.

Rucaparib Induces Responses in Men With Metastatic Castration-Resistant Prostate Cancer

May 19, 2020

“Although PARP inhibitor treatment has demonstrated radiographic and PSA responses in patients with BRCA alterations (4–8), the data presented here offer compelling evidence that response to PARP inhibitors is limited in men with mCRPC harboring an ATM, CDK1/2, or CHEK2 alteration."